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Current treatments for pediatric patients who have had myocardial ischemia-reperfusion injury include inotropic and mechanical circulatory support. Recovery of myocardial function after extracorporeal membrane oxygenation (ECMO) support is inconsistent, as reflected by a 40% failure to separate from ECMO. 1 Mitochondrial damage and dysfunction contribute significantly to the myocardial dysfunction in such patients with ischemia-reperfusion injury. 2 A novel strategy to repair and replenish damaged mitochondria, termed mitochondrial autotransplantation, has been developed in which healthy autologous mitochondria harvested from nonischemic skeletal muscle are transplanted into injured myocardium. 3 Previous reports have demonstrated that transplanted mitochondria restore mitochondrial function and viability and improve postischemic myocardial function by internal and extracellular mechanisms that include high-energy synthesis, transcriptomic and proteomic alteration, and DNA repair.
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MATERIALS AND METHODS
Pediatric patients who required central ECMO support for ischemiareperfusion-associated myocardial dysfunction after cardiac surgical procedure were eligible for mitochondrial autotransplantation. Patients were included if they had a myocardial ischemic event after cardiac surgery that was not ameliorated by surgical intervention and ECMO support. Patients were excluded if they underwent ECMO cannulation through peripheral vessels (cervical or femoral), because access for myocardial injections is not possible with this approach.
Mitochondrial harvest and isolation can be performed within 20 to 30 minutes during the same procedure and involves minimal manipulation of muscle tissue. Review of the proposed therapy was provided by 2 independent physicians who were not involved with the patient's care, and families were extensively counseled regarding the potential risks of the procedure. The treatment was provided under an Innovative Therapies protocol developed by the Boston Children's Hospital's institutional review board.
In all patients, the mediastinum was accessed and epicardial echocardiography was performed to identify regions of myocardial akinesis or hypokinesis. A 6 3 6-mm piece of healthy rectus abdominis muscle was harvested from the inferior aspect of the field by sharp dissection (Figure 1, A) . Autologous mitochondria (1 3 10 8 AE 1 3 10 5 ) were isolated under sterile conditions and suspended in 1 mL respiration buffer. 2, 5 Ten 100-mL injections containing 1 3 10 7 AE 1 3 10 4 mitochondria each were delivered by direct injection with a 1-mL tuberculin syringe (28-gauge needle) to the myocardium affected by ischemia-reperfusion, as identified by epicardial echocardiography (Figure 1 , B). Epicardial echocardiography was performed at the conclusion of the procedure to assess the presence of myocardial hematoma related to injections. Echocardiograms were read by a blinded reviewer for both global and regional dysfunction segments during the time reported (Videos 1 and 2).
RESULTS
The characteristics and outcomes (mortality and global cardiac function and regional hypokinesis segments) of the patients who underwent mitochondrial autotransplantation are described in Table 1 . None of the patients had arrhythmias or bleeding related to epicardial injections. Of the 5 subjects, 4 demonstrated improvement in ventricular function and were successfully separated from ECMO support.
DISCUSSION
This report describes the use of mitochondrial autotransplantation for myocardial recovery in pediatric patients who require ECMO support as a result of ischemia-reperfusion injury. Patients did not have adverse short-term complications related to mitochondrial injection (arrhythmia, intramyocardial hematoma, or scarring), and all demonstrated improvement in ventricular function within several days after treatment. Mitochondrial therapy is most advantageous if delivered as soon after ischemic injury as possible, as evidenced by studies in animal models. The patients in this series, however, were selected because they showed no recovery of myocardial function despite 1 to 2 days of ECMO support, and spontaneous recovery of ventricular function did not seem likely. Future studies investigating the optimal timing of therapy are necessary. It is possible that ventricular function might have improved without mitochondrial autotransplantation, and a randomized clinical trial is therefore necessary to demonstrate the efficacy of the strategy.
The dose of mitochondria and the method of delivery in this study were based on previous animal experience and extrapolated to human patient cardiac mass. 2 Future dose escalation studies are necessary to determine the optimal dose of mitochondria necessary in human patients. Although epicardial injection was used in this study, alternative delivery methods, including transcoronary delivery, are currently under investigation.
There was no detectable difference between preinjection and postinjection markers of systemic inflammatory response syndrome (as evidenced by stable respiratory and renal status), in agreement with animal study data. 2 Autopsy of patient 1 revealed no signs of inflammation or rejection at the sites of injection, and white blood cell counts had no clinically relevant change.
CONCLUSIONS
These cases demonstrate the first clinical application of a novel technique of mitochondrial autotransplantation that may be useful for patients with ischemia-reperfusion injury. 
